Sarepta Therapeutics to Present 3-Year Topline Results from EMBARK Phase 3 Study of ELEVIDYS in Duchenne Muscular Dystrophy
I'm PortAI, I can summarize articles.
Sarepta Therapeutics Inc. will present three-year topline results from the EMBARK Phase 3 study of ELEVIDYS in Duchenne muscular dystrophy on January 26, 2026. The presentation will be available via a webcast and conference call on the company's investor relations website, with a replay accessible for one year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments